People's Journal of Scientific Research
Published June 1, 2016 | Version v1
Journal article Open

Latanoprost Timolol Regime Vs Brimonidine Timolol Regime in Primary Open Angle Glaucoma Uncontrolled with Timolol Alone

Authors/Creators

Description

A randomized, prospective, interventional comparative study was conducted in 50 patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) for 13 months. The eyes were categorized as Group Aconsisting 48 eyes and group B consisting 48 eyes. The purpose of the study was to compare the efficacy and safety of treatment regimens with a combination of 'Latanoprost with Timolol' and 'Brimonidine with Timolol' in patients of primary open angle glaucoma uncontrolled with timolol alone. Patients of group A were given a combination of Latanoprost 0.005% with timolol 0.5% once daily and group B were given a combination of Brimonidine 0.2% with timolol 0.5% twice daily. The outcomes were difference from baseline to month 6 in mean IOP reduction, mean best corrected visual acquity (BCVA), mean vertical cup:disc ratio (CDR), mean average retinal nerve fibre layer (RNFL) thickness, mean average rim area, mean deviation (MD) and pattern standard deviation (PSD). Mean baseline IOPlevels in mmHg were 27.58(SD 3.28) in group A and 28.08(SD 3.11) in group B. At month 6, levels were 15.64(SD 1.42) in group Aand 17.27(SD 2.35) in group B. Outcome at 6 month in BCVA, CDR, average RNFLand average rim area also showed significant difference between the groups. The adverse events occurred equally, 42 in group Aand 44 in group B. The combination of Latanoprost/Timolol given once daily has more efficacy, equal safety and tolerability as compared to the combination of Brimonidine/Timolol given twice daily.

Files

2.pdf

Files (222.1 kB)

Name Size Download all
md5:60327f00af74c95ec3ac001a97e69b44
222.1 kB Preview Download

Additional details

References

  • 1. Fronimopoulos J, Lascaratos J. The terms glaucoma and cataract in the ancient Greek and Byzantine writers. Doc Ophthal 1991;77 (4):369-375.
  • 2. Thylefors B, Négrel AD, Pararajasegaram R, et al. Global data on blindness [review]. Bull World Health Org 1995;73(1):115-121.
  • 3. O'Connor DJ, Martone JF, Mead AM. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836–7.
  • 4. Diestelhorst M , Almegård B. Comparison of two fixed combinations of latanoprost and timolol in penangle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1998;236:577–81.
  • 5. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–1185
  • 6. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost. a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(suppl 1):S105–S115.
  • 7. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–484.
  • 8. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twicedaily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(suppl 2):S361–S368.
  • 9. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27: 135–142.
  • 10. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure: in the normal eye. Arch Ophthalmol. 1978;96:2045–2048.
  • 11. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120: 915–922.
  • 12. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899.
  • 13. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-fourhour control with latanoprost- timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898–902.
  • 14. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch phthalmol. 1997;115: 847–852.
  • 15. Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70–76.
  • 16. Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive herapies. Br J Ophthalmol. 2004; 88:1295–1298.
  • 17. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8–14.
  • 18. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51–5
  • 19. AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40.
  • 20. Jayachanderdas, Ziachaudhary, Profile of glaucoma in major eye hospital in north India;2001:49,25-30
  • 21. Gordon, Mae O., et al. "The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma." Archives of ophthalmology 120.6 (2002): 714-720
  • 22. Leske, M. Cristina, et al. "The Barbados Eye Study: prevalence of open angle glaucoma." Archives of ophthalmology 112.6 (1994): 821-829.
  • 23. Rudnicka, Alicja R., et al. "Variations in primary openangle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis." Investigative ophthalmology & visual science 47.10 (2006): 4254-4261
  • 24. King, A. J. W., et al. The rates of blindness and of partial sight registration in glaucoma patients. Eye 14.4 (2000): 613-619.
  • 25. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmo 2000;130(4):429–440.
  • 26. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48–56
  • 27. Kampik A , Arias-Puente A, O'Brart DPS, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002;11:90.
  • 28. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131:631–5.
  • 29. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther2000;16:251–9.
  • 30. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48–56.
  • 31. Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487–97
  • 32. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open- angl e gl aucoma . Ar ch Ophtha lmol 2002;120:701–13.
  • 33. Güliz Fatma YAVAŞ*, Tuncay KÜSBECİ, Onur POLAT, Mahmut KARADAŞ, Sıtkı Samet ERMİŞ, Ümit Übeyt İNAN. Comparison of latanoprost, brimonidine tartrate, and bimatoprost plus timolol maleate in fixed combinations: a retrospective, observational study Turkish Journal of Medical Sciences 12; 321 – 25.
  • 34. Schwenn O, Heckmann B, Guzy C, Miller PJ. Longterm effect of Latanoprost/Timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol 2010; 10: 21
  • 35. Kanamori A, Nagai-Kusuhara A, Escafio MFT, Maeda H, Nakamura M, Negi A. Comparison of confocal scanning laser ophthalmoscopy, scanning laser polarimetry and optical coherence tomography to discriminate ocular hypertension and glaucoma at an early stage. Graefes Arch Clin Exp Ophthalmol 2006; 244: 58–68
  • 36. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126: 1030–6